Chemomab shares surge 19.21% after-hours as CEO to present at Oppenheimer Healthcare Conference.

Chemomab Therapeutics (Nasdaq: CMMB) surged 19.21% in after-hours trading following news that CEO Dr. Adi Mor and senior management will present at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The event includes a live webcast of the corporate presentation and 90-day availability on the company’s investor relations site, alongside one-on-one investor meetings. The announcement highlights Chemomab’s progress in developing nebokitug, a first-in-class monoclonal antibody targeting fibro-inflammatory diseases, which has received FDA and EMA Orphan Drug designations and Fast Track status for primary sclerosing cholangitis. The conference exposure likely boosted investor optimism about the company’s clinical pipeline and regulatory milestones.